Search Results 521-530 of 17858 for Coagulation

  1. Study Comparing NOVOCART 3D and Microfracture Surgery for Treatment of Articular Knee Cartilage - Mayo Clinic

    Documented coagulation disorders or thromboembolic disease. Any currently active diagnosis of endocrine disorder without satisfactory treatment (ie ...

  2. Publications - Drew N. Rosenbaum, M.D. - Mayo Clinic

    Venous gangrene and intravascular coagulation and fibrinolysis in a patient treated with rivaroxaban. Am J Med. 2014 Jun; 127(6):e7-8. Epub 2014 Feb 22 ...

  3. A Study of TRK-950 in Patients With Advanced Solid Tumors - Mayo Clinic

    No clinically significant abnormalities. Acceptable coagulation status: For the Dose Escalation Cohort which completed enrollment November 2017. PT ≤ within ...

  4. https://www.mayoclinic.org/arabic_procedure_concepts.xml

  5. https://www.mayoclinic.org/chinese_organization_concepts.xml

  6. Endoscopy Clinical Trials - Mayo Clinic Research

    ... Coagulation Technique Scottsdale/Phoenix, AZ; Jacksonville, FL. The purpose of this study is to investigate if Hybrid Argon Plasma Coagulation (HAPC) is non ...

  7. A Study to Evaluate Intravenous Iloprost in Subjects with Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis - Mayo Clinic

    Subjects with a risk of clinically significant bleeding events, including those with coagulation or platelet disorders at screening. Subjects with a history ...

  8. Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma - Mayo Clinic

    ... coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre ...

  9. A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia - Mayo Clinic

    Following discontinuation of heparin, participants cannot be treated with a non-heparin anti-coagulant for ≥ 60 hours. 3. Current renal dialysis. 4 ...

  10. Trial of 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs (TRACY-1) - Mayo Clinic

    * Adequate hematologic, hepatic and coagulation function. Exclusion Criteria: * History of severe hypersensitivity (Grade ≥3) to any of the components or ...